Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

ARINA-1

Phase 3Small molecule

RRenovion, Inc.

1

Indications

3

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Pre-Bronchiolitis Obliterans SyndromeRecruiting

Pre-Bronchiolitis Obliterans SyndromePhase 3

Recruiting

Timeline

Expected Milestones

Q3 2028

Phase 3Recruiting

Pre-Bronchiolitis Obliterans Syndrome

NCT05654922

Clinical

Trials by Indication[1]

Safety and Efficacy1 trial

An Investigator-initiated Study to Evaluate Safety and Efficacy of ARINA-1 in People With a Tracheostomy

Withdrawn·MMatthew Bruehl·Phase 1·NCT05658029

Cystic Fibrosis1 trial

Phase 2a, 28-day Investigational Use Study of ARINA-1 in Non-Cystic Fibrosis Bronchiectasis (NCFBE) With Excess Mucus and Cough

Completed·RRenovion, Inc.·Phase 2·NCT05495243·40 enrolled

Pre-Bronchiolitis Obliterans Syndrome1 trial

A Phase 3, Open-label, Randomized, Standard of Care-controlled, Parallel Study Arm Study to Demonstrate Efficacy and Safety of ARINA-1 in the Prevention of Bronchiolitis Obliterans Syndrome (BOS) Progression in Participants With a Bilateral Lung Transplant

Recruiting·RRenovion, Inc.·Phase 3·NCT05654922·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for ARINA-1. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ARINA-1 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ARINA-1. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Renovion, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: RRenovion, Inc.

Related News